Literature DB >> 25873506

B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model.

Aaron C Shaver1, Bruce W Greig2, Claudio A Mosse3, Adam C Seegmiller2.   

Abstract

OBJECTIVES: Optimizing a clinical flow cytometry panel can be a subjective process dependent on experience. We develop a quantitative method to make this process more rigorous and apply it to B lymphoblastic leukemia/lymphoma (B-ALL) minimal residual disease (MRD) testing.
METHODS: We retrospectively analyzed our existing three-tube, seven-color B-ALL MRD panel and used our novel method to develop an optimized one-tube, eight-color panel, which was tested prospectively.
RESULTS: The optimized one-tube, eight-color panel resulted in greater efficiency of time and resources with no loss in diagnostic power.
CONCLUSIONS: Constructing a flow cytometry panel using a rigorous, objective, quantitative method permits optimization and avoids problems of interdependence and redundancy in a large, multiantigen panel. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Flow cytometry; Minimal residual disease; Optimization; Statistical analysis

Mesh：

Substances：

Year:  2015        PMID： 25873506     DOI： 10.1309/AJCPOOJRAVUN75GD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  5 in total

1.  A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Authors:  Michael Keeney; Brent L Wood; Benjamin D Hedley; Joseph A DiGiuseppe; Maryalice Stetler-Stevenson; Elisabeth Paietta; Gerard Lozanski; Adam C Seegmiller; Bruce W Greig; Aaron C Shaver; Lata Mukundan; Howard R Higley; Caroline C Sigman; Gary Kelloff; J Milburn Jessup; Michael J Borowitz
Journal:  Cytometry B Clin Cytom       Date:  2017-05-05       Impact factor: 3.058

2.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

3.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

4.  CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Caroline B Blunck; Eugênia Terra-Granado; Elda P Noronha; Gabriel Wajnberg; Fábio Passetti; Maria S Pombo-de-Oliveira; Mariana Emerenciano
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-30

Review 5.  Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.

Authors:  Marta Malczewska; Kamil Kośmider; Kinga Bednarz; Katarzyna Ostapińska; Monika Lejman; Joanna Zawitkowska
Journal:  Cancers (Basel)       Date:  2022-04-16       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.